Table 1.
Sample composition.
Fig 1.
A. Principal Components Analysis, using allele frequencies calculated for each population, analyzed via Past 3 software package. http://folk.uio.no/ohammer/past/. B. Hierarchical clustering using Euclidean Distance as a metric, using the Past3 software package, based on the allele frequencies for each population (see also Methods for details). The two distinct population subgroups are indicated with different colors.
Table 2.
Outline of the significant differences (p-values<0.05 in boldface) of the prevalence of actionable PGx biomarkers in European populations, compared to the average European.
Fig 2.
Comparison of the frequencies (vertical axis; %) of the 36 actionable PGx biomarkers (depicted at the horizontal axis) among European, Saudi Arabian and South African populations.
Fig 3.
Frequency of the clinically actionable genotypes in the European patients analyzed using the Affymetrix DMET™ Plus platform.
Green depicts genotypes with no actionable pharmacogenomic biomarkers, yellow depicts genotypes with at least one actionable pharmacogenomic biomarker, and red depicts genotypes with at least one high-risk actionable pharmacogenomic biomarker. As stated in PharmGKB, the term “actionable” does not discuss genetic or other testing for gene/protein/chromosomal variants, but does contain information about changes in efficacy, dosage or toxicity due to such variants.
Table 3.
Outline of the predicted average warfarin dosage calculation for all populations.
This table suggests the weekly average dosage along with the standard deviation, confidence interval (95%) and the respective upper bound and lower bound for each population.
Fig 4.
A. Average predicted warfarin dose across individuals for each population. Values for height, weight and age were approximated and set equal as the average of Caucasian racial group and subsequently used along with individual genotypes for CYP2C9 and VKORC1 pharmacogenes. B. Average predicted warfarin dose across individuals for each population corrected against the average European dose. Predicted doses were simulated using IWPC.
Fig 5.
Distribution of the different individuals analyzed for each population group using the Affymetrix DMET™ Plus platform for the predicted weekly warfarin dose (mg).